OPKO Health (NASDAQ:OPK – Get Rating)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research report issued on Thursday, Benzinga reports. They currently have a $3.00 target price on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 141.94% from the stock’s current price.
OPKO Health Price Performance
NASDAQ:OPK opened at $1.24 on Thursday. The firm has a market cap of $958.09 million, a PE ratio of -2.82 and a beta of 1.64. OPKO Health has a 12 month low of $1.00 and a 12 month high of $3.78. The company has a quick ratio of 1.50, a current ratio of 1.85 and a debt-to-equity ratio of 0.13. The company’s 50-day moving average price is $1.27 and its two-hundred day moving average price is $1.58.
OPKO Health (NASDAQ:OPK – Get Rating) last released its quarterly earnings results on Thursday, February 23rd. The biotechnology company reported ($0.11) EPS for the quarter, meeting analysts’ consensus estimates of ($0.11). The firm had revenue of $185.40 million for the quarter, compared to analyst estimates of $168.21 million. OPKO Health had a negative net margin of 32.70% and a negative return on equity of 15.77%. The company’s revenue for the quarter was down 53.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.11) earnings per share. On average, equities analysts anticipate that OPKO Health will post -0.32 EPS for the current fiscal year.
Insider Transactions at OPKO Health
Institutional Investors Weigh In On OPKO Health
Institutional investors and hedge funds have recently modified their holdings of the business. Guggenheim Capital LLC bought a new stake in shares of OPKO Health during the first quarter worth approximately $38,000. Point72 Hong Kong Ltd bought a new stake in OPKO Health in the first quarter valued at approximately $39,000. Humankind Investments LLC bought a new stake in OPKO Health in the third quarter valued at approximately $25,000. Zacks Investment Management bought a new stake in OPKO Health in the third quarter valued at approximately $25,000. Finally, Beacon Pointe Advisors LLC bought a new stake in OPKO Health in the first quarter valued at approximately $49,000. 23.49% of the stock is owned by institutional investors.
OPKO Health Company Profile
OPKO Health, Inc is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment includes the clinical laboratory operations of BioReference, as well as point-of-care operations.
- Get a free copy of the StockNews.com research report on OPKO Health (OPK)
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
- How to Buy High Yielding Dividend Stocks
- Oracle Has Spoken: Shares Fall 5%
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.